Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Roche bets $1B+ on DualityBio's ADC tech to tackle TOPO1 resistance

DualityBio said Friday it will receive $45 million upfront from Roche’s Genentech to develop drugs that could be part of a new wave of antibody-drug conjugates. The deal is centered on ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Friday 28 August →